Market News
Smart Trading. Simplified.
Jeff Bezos' Next Big Thing
The tech visionary who built a revolutionary $1.6 trillion company from scratch is quietly pouring his riches into a secretive project that could mean the end of Alzheimer's.
Early investors who get in by June 2, 2021, could turn every $1,000 into $1.1 million.
Is Apollo Medical Stock A Buy?
Is Apollo Medical Stock A Buy? The American healthcare system is quite a complex thing, to say the least. A completely separate beast from, say, the Canadian healthcare system or the United Kingdom’s healthcare system, the United States definitely stands alone in the world, for better or for worse. One of the things that sets […]
A Rare Opportunity to Turn $1,000 into $461,800
On August 30, 2019, a small firm won a contract from the Pentagon to build a strange new weapon. The Joint Chiefs of Staff calls this new weapon "Unstoppable." This under-the-radar company is not yet a household name.
Our research proves that anyone who gets in now could turn $1,000 into $461,800 >>>
Roblox Stock Predictions
Roblox Corporation [NYSE: RBLX] is an online game platform and game creation system that brings players and developers together to imagine, create, and share experiences with each other in immersive, user-generated 3D worlds. It allows users to develop and play games created by other users. All the online games on the platform are built by […]
The World's First $2 Trillion Drug?
The Wall Street Journal reports new treatment is "transforming medicine."
Bill Gates writes that it could "help humanity."
Ark Investments think it could be a "$2 trillion market."
And one small company owns the patent on it.
This unknown biotech's stock is set to surge 46,751% >>>
Is JinkoSolar Stock A Buy?
With the success of Tesla (TSLA) — both on the car market and the stock market — it’s no surprise to learn that there are plenty of retail investors and traders in search of the next great alternative energy company. From General Electric’s line of products for the home to Vestas’ iconic wind farms spread […]
"The Biggest Drug Ever"
On August 23, 2018, a small biotech won a patent for a treatment that could help as many as 50 million people and save the U.S. as much as $20 TRILLION. Jim Cramer says a drug like this would be "The Biggest Drug Ever."
Our research shows that anyone who gets in today could turn every $1,000 into $1.1 million >>>
Is BioCryst Pharmaceuticals A Buy?
Headquartered in Durham, North Carolina, BioCryst Pharmaceuticals is a small-cap stock with promise. Indeed, analysts have pegged the stock as a “Strong Buy.” The biotech company researches small-molecule and oral medications. Its peramivir injection is used to treat acute influenza under the trademarked names of PERMAIFLU, RAPIACTA, and RAPIVAB. Galidesivir and Its Impact on COVID-19 […]
Is Biden About to Ban Bitcoin?
Bitcoin could crash soon. And even if you don't have a penny in cryptos YOU are going to feel the impact. The government is so afraid of cryptocurrency that some worry Biden will ban Bitcoin using a "backdoor" approach. Investors who know what to do could grow their money 60-fold in the months ahead.
Is SoFi The Amazon Of Financial Services?
These days, it seems like every business wants to “the Amazon of [insert industry name].” That applies to financial services just as much as it does to selling cars and completing taxes. More often than not, people mean that a company provides a lot of services and dominates an industry when they call it “the […]
Small Biotech Could Soar 1,000%
There's no sector poised to deliver bigger gains in 2021 than small-cap biotech stocks.
In the past year alone...
Novavax Inc jumped from $6.26 to $270.51, a gain of 3,396%.
Aclaris Therapts jumped from $0.70 to $24.28 an increase of 1,583%.
Vaxart Inc rocketed from $0.97 to $14.94, a 1,083% jump.
Here's the next biotech we think could soar 1,000% >>>
View this email online if it doesn't display correctly. This newsletter is not financial advice. Please read our Disclaimer.
To unsubscribe from Financhill, click here.
PO Box 126
Catasauqua, PA 18032
Financhill is not an investment advisor and is not registered with the U.S. Securities and Exchange Commission or the Financial Industry Regulatory Authority. Further, owners, employees, agents or representatives of Financhill are not acting as investment advisors and might not be registered with the U.S. Securities and Exchange Commission or the Financial Industry Regulatory.
The sender of this email makes no representations or warranties concerning the products, practices or procedures of any company or entity mentioned or recommended in this email, and makes no representations or warranties concerning said company or entity's compliance with applicable laws and regulations, including, but not limited to, regulations promulgated by the SEC or the CFTC. The sender of this email may receive a portion of the proceeds from the sale of any products or services offered by a company or entity mentioned or recommended in this email. The recipient of this email assumes responsibility for conducting its own due diligence on the aforementioned company or entity and assumes full responsibility, and releases the sender from liability, for any purchase or order made from any company or entity mentioned or recommended in this email.
The content on any of Financhill websites, products or communication is for educational purposes only. Nothing in its products, services, or communications shall be construed as a solicitation and/or recommendation to buy or sell a security. Trading stocks, options and other securities involves risk. The risk of loss in trading securities can be substantial. The risk involved with trading stocks, options and other securities is not suitable for all investors. Prior to buying or selling an option, an investor must evaluate his/her own personal financial situation and consider all relevant risk factors. See: Characteristics and Risks of Standardized Options. The Financhill.com educational training program and software services are provided to improve financial understanding.
The information presented in this site is not intended to be used as the sole basis of any investment decisions, nor should it be construed as advice designed to meet the investment needs of any particular investor. Nothing in our research constitutes legal, accounting or tax advice or individually tailored investment advice. Our research is prepared for general circulation and has been prepared without regard to the individual financial circumstances and objectives of persons who receive or obtain access to it. Our research is based on sources that we believe to be reliable. However, we do not make any representation or warranty, expressed or implied, as to the accuracy of our research, the completeness, or correctness or make any guarantee or other promise as to any results that may be obtained from using our research. To the maximum extent permitted by law, neither we, any of our affiliates, nor any other person, shall have any liability whatsoever to any person for any loss or expense, whether direct, indirect, consequential, incidental or otherwise, arising from or relating in any way to any use of or reliance on our research or the information contained therein. Some discussions contain forward looking statements which are based on current expectations and differences can be expected. All of our research, including the estimates, opinions and information contained therein, reflects our judgment as of the publication or other dissemination date of the research and is subject to change without notice. Further, we expressly disclaim any responsibility to update such research. Investing involves substantial risk. Past performance is not a guarantee of future results, and a loss of original capital may occur. No one receiving or accessing our research should make any investment decision without first consulting his or her own personal financial advisor and conducting his or her own research and due diligence, including carefully reviewing any applicable prospectuses, press releases, reports and other public filings of the issuer of any securities being considered. None of the information presented should be construed as an offer to sell or buy any particular security. As always, use your best judgment when investing.
Past performance is no guarantee of future performance. This product is for educational purposes only. Practical application of the products herein are at your own risk and Financhill.com, its partners, representatives and employees assume no responsibility or liability for any use or mis-use of the product. Please contact your financial advisor for specific financial advice tailored to your personal circumstances. Any trades shown are hypothetical example and do not represent actual trades. Actual results may differ. Nothing here in constitutes a recommendation respecting the particular security illustrated.
No comments:
Post a Comment